Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
14. Mai 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, May 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present new...
Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology
27. April 2020 08:30 ET
|
Myovant Sciences, Inc.
Abstracts accepted for presentation in oral and poster sessions at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific MeetingTreatment with relugolix...
Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
22. April 2020 07:30 ET
|
Myovant Sciences, Inc.
Co-primary endpoints met with 75.2% response rate for dysmenorrhea (menstrual pain) (p < 0.0001) and 66.0% response rate for non-menstrual pelvic pain (p < 0.0001)Women receiving relugolix...
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
21. April 2020 16:05 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced it will...
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
21. April 2020 08:30 ET
|
Myovant Sciences, Inc.
Positive Phase 3 results with 96.7% response rate in men with advanced prostate cancer form the basis of the submissionMyovant expects to submit a second NDA for relugolix combination tablet for women...
Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
14. April 2020 08:30 ET
|
Myovant Sciences, Inc.
Initiative to spotlight diverse, personal stories about menstruation in partnership with storytelling nonprofit The Moth HealthyWomen joins Female Forward Together, a cross-sector coalition committed...
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
31. März 2020 02:00 ET
|
Myovant Sciences, Inc.
Gedeon Richter to commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, Russia - CIS, Latin America, Australia, and New ZealandMyovant to receive an upfront...
Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
10. März 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, March 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today...
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
09. März 2020 08:30 ET
|
Myovant Sciences, Inc.
If approved, relugolix combination tablet would offer a one pill, once-a-day treatment option for women with uterine fibroidsNew Drug Application to the U.S. Food and Drug Administration planned for...
Myovant Sciences to Present at Upcoming March Investor Conferences
25. Februar 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today...